G. Liu

LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study

Benjamin Solomon, Todd M. Bauer, Filippo de Marinis et al. · Annals of Oncology · 2020 · 23 citations

Medicine, Oncology, Pharmacology +11

BM-32 * CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

Alice T. Shaw, Ranee Mehra, Daniel S.W. Tan et al. · Neuro-Oncology · 2014 · 21 citations · Full text

Medicine, Oncology, Pharmacology +15

LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen

Siow Ming Lee, Christian Schulz, K. Prabhash et al. · Annals of Oncology · 2022 · 21 citations · Full text

Medicine, Oncology, Pharmacology +10

319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC

J.C-H. Yang, G. Liu, S. Lu et al. · Annals of Oncology · 2022 · 17 citations

Medicine, Pharmacology, Pharmacotherapy +6

Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

D. Kim, Ranee Mehra, D.S.W. Tan et al. · International Journal of Radiation Oncology*Biology*Physics · 2014 · 14 citations · Full text

Medicine, Oncology, Pharmacology +14